Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Comparison of the Anti-Inflammatory Effects of Mouse Adipose- and Bone-Marrow-Derived Multilineage-Differentiating Stress-Enduring Cells in Acute-Phase Spinal Cord Injury.

Nagaoki T., Kumagai G., Nitobe Y., Sasaki A., Fujita T., Fukutoku T.

Clinical Trial on Spinal Cord Injury, Chronic Inflammation, published in J Neurotrauma (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Neurotrauma (2023)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
37051701
DOI
10.1089/neu.2022.0470

Abstract (original English)

Abstract Spinal cord injury (SCI) is a serious neurological disorder, with the consequent disabilities conferred by this disorder typically persisting for life. Multilineage-differentiating stress-enduring (Muse) cells are endogenous stem cells that can be collected from various tissues as well as from mesenchymal stem cells (MSCs); additionally, these Muse cells are currently being used in clinical trials. The anti-inflammatory effect of stem cell transplantation prevents secondary injuries of SCI; however, its effect on Muse cells remains unclear. In this study, we aimed to compare the anti-inflammatory effects of adipose (AD)- and bone marrow (BM)-Muse cells that were isolated from mice (6-week-old C57BL/6J) following intralesional administration during the acute phase of SCI. Flow cytometry was used to isolate Muse cells from AD and BM MSCs. The percentage of Muse cells was 3.9 and 2.7% for AD and BM MSCs, respectively. To examine cell viability, Muse cells were incubated under H 2 O 2 -induced oxidative stress conditions. Overall, AD-Muse cells exhibited higher viability than BM-Muse cells ( p = 0.032). In enzyme-linked immunosorbent assay analysis, AD-Muse cells displayed greater secretion of brain-derived neurotrophic factor (BDNF; p = 0.008), vascular endothelial growth factor ( p = 0.032), and hepatocyte growth factor ( p = 0.016). DNA microarray analysis revealed high

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
MiceAnimalsBrain-Derived Neurotrophic FactorBone MarrowVascular Endothelial Growth Factor AAlprostadilHydrogen PeroxideMice, Inbred C57BLSpinal Cord InjuriesSpinal Cord

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research